49799 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Novus Biologicals anti dog1 tmem16a
    Niclosamide inhibits expression of MUC5AC and SPDEF in Calu-3 cells. ( A ) Western blot indicating upregulation of <t>TMEM16A</t> in Calu-3 cells by IL-13 (20 ng/mL, 72 h) and inhibition of expression by niclosamide (1 µM). Blots were performed in triplicates. ( B ) RT-PCR analysis of the expression of MUC5AC, TMEM16A, and SAM pointed domain-containing ETS transcription factor (SPDEF) in Calu-3 airway epithelial cells. SPDEF is an integrator of goblet cell differentiation and pulmonary Th2 inflammation. ( C ) Low cycle numbers (20×) were chosen for quantification of expression by relating specific signals to expression of the housekeeper protein GAPDH. IL-13 (20 ng/mL) leads to upregulation of expression of MUC5AC, TMEM16A, and SPDEF. Niclosamide (Niclo, 1 µM, 72 h) strongly inhibits expression of MUC5AC, TMEM16A, and SPDEF. Mean ± SEM (number of assays). #,§ significant increase by IL-13 and inhibition by niclosamide, respectively ( p
    Anti Dog1 Tmem16a, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti dog1 tmem16a/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti dog1 tmem16a - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    Image Search Results


    Niclosamide inhibits expression of MUC5AC and SPDEF in Calu-3 cells. ( A ) Western blot indicating upregulation of TMEM16A in Calu-3 cells by IL-13 (20 ng/mL, 72 h) and inhibition of expression by niclosamide (1 µM). Blots were performed in triplicates. ( B ) RT-PCR analysis of the expression of MUC5AC, TMEM16A, and SAM pointed domain-containing ETS transcription factor (SPDEF) in Calu-3 airway epithelial cells. SPDEF is an integrator of goblet cell differentiation and pulmonary Th2 inflammation. ( C ) Low cycle numbers (20×) were chosen for quantification of expression by relating specific signals to expression of the housekeeper protein GAPDH. IL-13 (20 ng/mL) leads to upregulation of expression of MUC5AC, TMEM16A, and SPDEF. Niclosamide (Niclo, 1 µM, 72 h) strongly inhibits expression of MUC5AC, TMEM16A, and SPDEF. Mean ± SEM (number of assays). #,§ significant increase by IL-13 and inhibition by niclosamide, respectively ( p

    Journal: International Journal of Molecular Sciences

    Article Title: Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

    doi: 10.3390/ijms22157852

    Figure Lengend Snippet: Niclosamide inhibits expression of MUC5AC and SPDEF in Calu-3 cells. ( A ) Western blot indicating upregulation of TMEM16A in Calu-3 cells by IL-13 (20 ng/mL, 72 h) and inhibition of expression by niclosamide (1 µM). Blots were performed in triplicates. ( B ) RT-PCR analysis of the expression of MUC5AC, TMEM16A, and SAM pointed domain-containing ETS transcription factor (SPDEF) in Calu-3 airway epithelial cells. SPDEF is an integrator of goblet cell differentiation and pulmonary Th2 inflammation. ( C ) Low cycle numbers (20×) were chosen for quantification of expression by relating specific signals to expression of the housekeeper protein GAPDH. IL-13 (20 ng/mL) leads to upregulation of expression of MUC5AC, TMEM16A, and SPDEF. Niclosamide (Niclo, 1 µM, 72 h) strongly inhibits expression of MUC5AC, TMEM16A, and SPDEF. Mean ± SEM (number of assays). #,§ significant increase by IL-13 and inhibition by niclosamide, respectively ( p

    Article Snippet: The primary antibody, anti-DOG1/TMEM16A (SP31, Novus Biologicals, USA) was incubated overnight at 4 °C.

    Techniques: Expressing, Western Blot, Inhibition, Reverse Transcription Polymerase Chain Reaction, Cell Differentiation

    Expression of MUC5AC and activation of TMEM16A in Calu-3 airway epithelial cells is inhibited by niclosamide. ( A ) Expression of MUC5AC induced by IL-13 (20 ng/mL; 72 h) in Calu-3 airway epithelial cells was inhibited by simultaneous incubation with niclosamide (1 µM). Bar = 100 µm. ( B ) Quantification of MUC5AC expression indicating inhibition by niclosamide (Niclo). ( C ) Current overlays from whole-cell patch clamp experiments before and after induction of MUC5AC expression by IL-13. Activation of whole-cell currents by purinergic stimulation (ATP, 100 µM) was enhanced by IL-13, which was completely inhibited by acute application of niclosamide (1 µM). ( D ) Corresponding current/voltage relationships. The inhibitor of Ca 2+ -activated KCNN4 K + channels, TRAM-34 (100 nM), was present in all patch clamp experiments to avoid potential activation of Ca 2+ -activated K + channels. Mean ± SEM (number of cells). * significant activation by ATP ( p

    Journal: International Journal of Molecular Sciences

    Article Title: Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

    doi: 10.3390/ijms22157852

    Figure Lengend Snippet: Expression of MUC5AC and activation of TMEM16A in Calu-3 airway epithelial cells is inhibited by niclosamide. ( A ) Expression of MUC5AC induced by IL-13 (20 ng/mL; 72 h) in Calu-3 airway epithelial cells was inhibited by simultaneous incubation with niclosamide (1 µM). Bar = 100 µm. ( B ) Quantification of MUC5AC expression indicating inhibition by niclosamide (Niclo). ( C ) Current overlays from whole-cell patch clamp experiments before and after induction of MUC5AC expression by IL-13. Activation of whole-cell currents by purinergic stimulation (ATP, 100 µM) was enhanced by IL-13, which was completely inhibited by acute application of niclosamide (1 µM). ( D ) Corresponding current/voltage relationships. The inhibitor of Ca 2+ -activated KCNN4 K + channels, TRAM-34 (100 nM), was present in all patch clamp experiments to avoid potential activation of Ca 2+ -activated K + channels. Mean ± SEM (number of cells). * significant activation by ATP ( p

    Article Snippet: The primary antibody, anti-DOG1/TMEM16A (SP31, Novus Biologicals, USA) was incubated overnight at 4 °C.

    Techniques: Expressing, Activation Assay, Incubation, Inhibition, Patch Clamp

    Activation of TMEM16A whole-cell currents is potentiated by brevenal. ( A ) Dose-dependent activation of endogenous TMEM16A whole-cell currents in CFBE airway epithelial cells, by the purinergic agonist ATP. Clamp voltages ± 100 mV in steps of 20 mV. ( B ) Corresponding current/voltage relationships. ( C , D ) Activation of whole-cell currents obtained from cells pre-incubated with brevenal (500 nM, 15 min) and corresponding current/voltage relationships. ( E ) Activation of whole-cell currents in brevenal-incubated cells, in which expression of TMEM16A has been knocked down by treatment with siRNA-TMEM16A (c.f. Supplementary Figure E2 ). ( F ) Corresponding current/voltage relationships. Mean ± SEM (number of cells). * significant activation by ATP ( p

    Journal: International Journal of Molecular Sciences

    Article Title: Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

    doi: 10.3390/ijms22157852

    Figure Lengend Snippet: Activation of TMEM16A whole-cell currents is potentiated by brevenal. ( A ) Dose-dependent activation of endogenous TMEM16A whole-cell currents in CFBE airway epithelial cells, by the purinergic agonist ATP. Clamp voltages ± 100 mV in steps of 20 mV. ( B ) Corresponding current/voltage relationships. ( C , D ) Activation of whole-cell currents obtained from cells pre-incubated with brevenal (500 nM, 15 min) and corresponding current/voltage relationships. ( E ) Activation of whole-cell currents in brevenal-incubated cells, in which expression of TMEM16A has been knocked down by treatment with siRNA-TMEM16A (c.f. Supplementary Figure E2 ). ( F ) Corresponding current/voltage relationships. Mean ± SEM (number of cells). * significant activation by ATP ( p

    Article Snippet: The primary antibody, anti-DOG1/TMEM16A (SP31, Novus Biologicals, USA) was incubated overnight at 4 °C.

    Techniques: Activation Assay, Incubation, Expressing

    Activation of TMEM16A by Eact induces mucus release and airway contraction. ( A ) Mucus staining by alcian blue in OVA-treated asthmatic mice. Acute application of the activator of TMEM16A, Eact (4.8 µg/mL intratracheal), induced acute release of mucus from goblet cells and increased intraluminal mucus. Bars indicate 50 µm. ( B ) Summary of intracellular and intraluminal mucus. ( C ) Summary of cross sectional area indicating airway contraction by Eact. Mean ± SEM (number of animals/number of measurements). # significant difference when compared to control ( p

    Journal: International Journal of Molecular Sciences

    Article Title: Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

    doi: 10.3390/ijms22157852

    Figure Lengend Snippet: Activation of TMEM16A by Eact induces mucus release and airway contraction. ( A ) Mucus staining by alcian blue in OVA-treated asthmatic mice. Acute application of the activator of TMEM16A, Eact (4.8 µg/mL intratracheal), induced acute release of mucus from goblet cells and increased intraluminal mucus. Bars indicate 50 µm. ( B ) Summary of intracellular and intraluminal mucus. ( C ) Summary of cross sectional area indicating airway contraction by Eact. Mean ± SEM (number of animals/number of measurements). # significant difference when compared to control ( p

    Article Snippet: The primary antibody, anti-DOG1/TMEM16A (SP31, Novus Biologicals, USA) was incubated overnight at 4 °C.

    Techniques: Activation Assay, Staining, Mouse Assay

    Expression of TMEM16A in human healthy, asthmatic, and CF lungs. Lung slices of normal airways indicate little expression of TMEM16A in both surface airway epithelium and airway submucosal glands. Pronounced expression of TMEM16A in apical membranes of surface epithelial cells and airway submucosal glands of patients with asthma and CF (brown precipitation, DAP staining). Submucosal glands were often found to be hypertrophic. Representative stainings of four patients each. Bars indicate 20 µm.

    Journal: International Journal of Molecular Sciences

    Article Title: Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

    doi: 10.3390/ijms22157852

    Figure Lengend Snippet: Expression of TMEM16A in human healthy, asthmatic, and CF lungs. Lung slices of normal airways indicate little expression of TMEM16A in both surface airway epithelium and airway submucosal glands. Pronounced expression of TMEM16A in apical membranes of surface epithelial cells and airway submucosal glands of patients with asthma and CF (brown precipitation, DAP staining). Submucosal glands were often found to be hypertrophic. Representative stainings of four patients each. Bars indicate 20 µm.

    Article Snippet: The primary antibody, anti-DOG1/TMEM16A (SP31, Novus Biologicals, USA) was incubated overnight at 4 °C.

    Techniques: Expressing, Staining